In this article, I argue that the social imaginaries that inform biomedical regulation circulate not only in technical spheres populated by experts but that they are equally articulated (and vehemently contested) in national public spheres in more popular forms of communication. I examine the relation between a national healthcare imaginary and the regulation of therapeutics through a public controversy about access to an innovative therapeutic indicated for spinal muscular atrophy. The establishment of the Danish Medicines Council, a new health technology assessment institution, and its decision to restrict access to an innovative therapeutic sparked controversy in 2017 involving political proponents, adversaries, and patients, among others. In a variety of ways, they rhetorically mobilized or contested the Danish universalist welfare imaginary which contains promises and prospects of solidarity, security, and absence of market forces in universal healthcare, including access to therapeutics. I use a combination of media content analysis and rhetorical close reading methods to analyze how the imaginary was drawn upon in arguments for and against the new regulatory institution.

中文翻译：

---

在丹麦规范患者获得治疗的机会：公共争议中福利想象的修辞分析

在本文中，我认为，为生物医学监管提供信息的社会想象不仅在由专家组成的技术领域传播，而且在国家公共领域以更流行的传播形式同样清晰地表达（并激烈争论）。我通过关于获得适用于脊髓性肌萎缩症的创新疗法的公开争议，研究了国家医疗保健想象与疗法监管之间的关系。丹麦医药委员会（一个新的卫生技术评估机构）的成立及其限制获得创新疗法的决定在 2017 年引发了争议，涉及政治支持者、对手和患者等。以多种方式，他们在口头上动员或反对丹麦普遍主义的福利想象，其中包含团结、安全和缺乏普遍医疗保健市场力量的承诺和前景，包括获得治疗。我结合媒体内容分析和修辞细读方法来分析在支持和反对新监管机构的争论中如何利用想象。